Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Agilent buys SynPro
April 24, 2006
| A version of this story appeared in
Volume 84, Issue 17
Agilent Technologies has paid an undisclosed sum for SynPro, a privately held contract manufacturer of synthetic nucleic acids. SynPro was established in December to acquire a manufacturing facility in Boulder, Colo., that supplies short synthetic DNA and RNA molecules for clinical trials. The deal will enable Agilent to offer a range of value-added services in the RNA synthesis market by wedding Agilent's platform for the analysis for DNA and RNA to the manufacturing capabilities of SynPro. Agilent estimates the combined RNA and DNA synthesis market is worth roughly $700 million per year and will grow at a 10 to 20% clip annually.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter